thiazoles has been researched along with Osteolysis in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (66.67) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
Chen, X; Cheng, Y; Fan, B; Wei, X; Yu, S; Zhang, A; Zhang, S; Zhao, H | 1 |
Brown, LG; Corey, E; Koreckij, T; Nguyen, H; Vessella, RL; Yu, EY | 1 |
Isoe, T; Kobayashi, Y; Kubo, K; Murooka, H; Nishitoba, T; Ohno, H; Shibuya, M; Yoneda, T | 1 |
3 other study(ies) available for thiazoles and Osteolysis
Article | Year |
---|---|
DAPT inhibits titanium particle-induced osteolysis by suppressing the RANKL/Notch2 signaling pathway.
Topics: Amyloid Precursor Protein Secretases; Animals; Cells, Cultured; Diamines; Enzyme Inhibitors; Mice, Inbred C57BL; Osteolysis; Prostheses and Implants; RANK Ligand; Receptor, Notch2; Signal Transduction; Thiazoles; Titanium | 2020 |
Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Bone Neoplasms; Cell Line, Tumor; Dasatinib; Docetaxel; Humans; Male; Mice; Mice, SCID; Osteolysis; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Taxoids; Thiazoles; Xenograft Model Antitumor Assays | 2009 |
A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model.
Topics: Acid Phosphatase; Animals; Bone Neoplasms; Cell Differentiation; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Isoenzymes; Mice; Mice, Transgenic; Osteoclasts; Osteolysis; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Mas; Rats; Rats, Inbred F344; Rats, Nude; Receptor, Macrophage Colony-Stimulating Factor; Tartrate-Resistant Acid Phosphatase; Thiazoles | 2006 |